Advertisement

Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial

Letter to the Editor

Keywords

Bevacizumab Optical Coherence Tomography Diabetic Retinopathy Macular Edema Retinal Vein Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The authors have full control of the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

References

  1. 1.
    Eter N, Mohr A, Wachtlin J et al (2016) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-016-3431-x PubMedCentralGoogle Scholar
  2. 2.
    Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMedGoogle Scholar
  3. 3.
    Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 124:193–198CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  5. 5.
    Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749CrossRefPubMedGoogle Scholar
  6. 6.
    Coscas G, Augustin A, Bandello F et al (2014) Retreatment with ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:1–9CrossRefPubMedGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMedGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2015) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 159:607–608CrossRefPubMedGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2016) Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study. Am J Ophthalmol 161:215–216CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-NapocaCluj-NapocaRomania

Personalised recommendations